학술논문
Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection.
Document Type
Academic Journal
Author
Hou MM; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; Barrett JR; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; Themistocleous Y; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Rawlinson TA; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Diouf A; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.; Martinez FJ; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.; Nielsen CM; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; Lias AM; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; King LDW; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; Edwards NJ; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Greenwood NM; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kingham L; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Poulton ID; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Khozoee B; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Goh C; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Hodgson SH; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; Mac Lochlainn DJ; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; Salkeld J; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; Guillotte-Blisnick M; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.; Huon C; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.; Mohring F; Department of Infection Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.; Reimer JM; Novavax AB, Kungsgatan 109, SE-753 18 Uppsala, Sweden.; Chauhan VS; International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.; Mukherjee P; Multi Vaccines Development Program (MVDP), New Delhi, India.; Biswas S; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Taylor IJ; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Lawrie AM; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Cho JS; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; Nugent FL; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Long CA; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.; Moon RW; Department of Infection Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.; Miura K; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.; Silk SE; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; Chitnis CE; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.; Minassian AM; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK.; Draper SJ; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Source
Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE
Subject
Language
English
Abstract
There are no licensed vaccines against Plasmodium vivax . We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% ( n = 6) compared with unvaccinated controls ( n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine.